In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Alexza Pharmaceuticals nets $47mm from IPO

Executive Summary

Alexza Pharmaceuticals, a biotech with a drug delivery technology and clinical-stage compounds that incorporate it, netted $47mm from its initial public offering in which it sold 6.325mm common shares (including the overallotment) at $8 apiece. When it filed the IPO in December 2005, Alexza had hoped to raise $86.25mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies